And I’m not going get any worse, I’m only going to get better,” she says of her expectations shortly before her first dose of Spinraza. The procedure by neuroradiologist Dr. Steve Seidman ...

The CHERISH study was a multicenter, randomized, double-blind, sham-procedure controlled study to evaluate the safety and efficacy of Spinraza in children with later-onset SMA (n=126) aged 2-12 years.

Biogen’s SPINRAZA® Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with SMA.

SMA disables the nerve signals controlling muscle movement. In clinical trials, Spinraza helped children stricken with SMA to hold up their heads, sit up, stand on their own, and walk short distances.

Biogen also released additional data from NURTURE, an eight-year, open-label study examining the use of 12 mg Spinraza in clinically presymptomatic infants. Results showed that 92% of participants ...

Eligible people may receive co-pay support for the cost of Spinraza and help with paying for Spinraza administration. For more information and to find out if you’re eligible for support, call ...

--Ionis Pharmaceuticals today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA ® in infants and toddlers living with spinal muscular atrophy.

A carton of Spinraza, Biogen’s new treatment for spinal muscular atrophy (SMA). The first year of treatment will cost $750,000, and $375,000 per year after that. Biogen ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe. GlobalData. Biogen’s higher dose Spinraza under review by US and EU regulators.

Spinraza, which is used to treat spinal muscular atrophy, can cause side effects. Learn about its mild and serious side effects and how to manage them.

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma. By James Waldron Jun 25, 2025 8:04am. Biogen Zolgensma (onasemnogene abeparvovec) ...

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with ...